Objective:To observe the effect of Icariin on diabetic myocardial hypertrophy and explore its molecular mechanism.Methods:C57BL/6 mice were randomly divided into Ctrl group(normal control group),DM group(STZ intraperi...Objective:To observe the effect of Icariin on diabetic myocardial hypertrophy and explore its molecular mechanism.Methods:C57BL/6 mice were randomly divided into Ctrl group(normal control group),DM group(STZ intraperitoneal injection model),and DM+ICA group(diabetic C57BL/6 mice by intragastric Icariin solution 80mg/kg/d,for 3 consecutive weeks).Real-time quantitative PCR was used to detect myocardial hypertrophy markers BNP andβ-MHC.Western blotting was used to detect myocardial AMPK,p-AMPK,mTOR,p-mTOR,LC3B and Beclin1 protein expression.Echocardiogram was used to detect left ventricular mass and ejection fraction.Results:Compared with the normal control group,the expression of myocardial hypertrophy markers BNP andβ-MHC mRNA in diabetic mice were significantly increased;the expression of phosphorylated AMPK protein,autophagy-related protein LC3B and Beclin1 were significantly increased,and the expression of phosphorylated mTOR protein is significantly reduced;the left ventricular mass is significantly increased.The above changes can be reversed after treatment with Icariin,but the effect of Icariin is blocked by the autophagy inhibitor rapamycin.Conclusion:Icariin may inhibit autophagy and reduce diabetic myocardial hypertrophy through AMPK-mTOR signaling pathway.展开更多
Background Vorapaxar reduces cardiovascular death, myocardial infarction （MI）, or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus （DM） are at high risk of recurrent t...Background Vorapaxar reduces cardiovascular death, myocardial infarction （MI）, or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus （DM） are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from antithrombotic therapies. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial was a randomized, double-blind, placebo-controlled trial of vorapaxar in patients with stable atherosclerosis.展开更多
基金Project of Medical and Health Research,Gansu Province(No.GSWSKY2020-13)。
文摘Objective:To observe the effect of Icariin on diabetic myocardial hypertrophy and explore its molecular mechanism.Methods:C57BL/6 mice were randomly divided into Ctrl group(normal control group),DM group(STZ intraperitoneal injection model),and DM+ICA group(diabetic C57BL/6 mice by intragastric Icariin solution 80mg/kg/d,for 3 consecutive weeks).Real-time quantitative PCR was used to detect myocardial hypertrophy markers BNP andβ-MHC.Western blotting was used to detect myocardial AMPK,p-AMPK,mTOR,p-mTOR,LC3B and Beclin1 protein expression.Echocardiogram was used to detect left ventricular mass and ejection fraction.Results:Compared with the normal control group,the expression of myocardial hypertrophy markers BNP andβ-MHC mRNA in diabetic mice were significantly increased;the expression of phosphorylated AMPK protein,autophagy-related protein LC3B and Beclin1 were significantly increased,and the expression of phosphorylated mTOR protein is significantly reduced;the left ventricular mass is significantly increased.The above changes can be reversed after treatment with Icariin,but the effect of Icariin is blocked by the autophagy inhibitor rapamycin.Conclusion:Icariin may inhibit autophagy and reduce diabetic myocardial hypertrophy through AMPK-mTOR signaling pathway.
文摘Background Vorapaxar reduces cardiovascular death, myocardial infarction （MI）, or stroke in patients with previous MI while increasing bleeding. Patients with diabetes mellitus （DM） are at high risk of recurrent thrombotic events despite standard therapy and may derive particular benefit from antithrombotic therapies. The Thrombin Receptor Antagonist in Secondary Prevention of Atherothrombotic Ischemic Events-TIMI 50 trial was a randomized, double-blind, placebo-controlled trial of vorapaxar in patients with stable atherosclerosis.
